Efficacy of adjuvant chemotherapy schedules for breast cancer according to body mass index: results from the phase III GIM2 trial

Francesca Poggio; Eva Blondeaux; Marco Tagliamento; Marta Perachino; Simone Nardin; Benedetta Conte; Mario Giuliano; Grazia Arpino; Michelino De Laurentiis; Adriano Gravina; Giancarlo Bisagni; Anita Rimanti; Anna Turletti; C. Nisticò; Emanuela Magnolfi; Simona Gasparro; Alessandra Fabi; Ornella Garrone; M.G. Alicicco; Ylenia Urracci; Paola Poletti; Pierpaolo Correale; Chiara Molinelli; Alessandra Fozza; Fabio Puglisi; G. Colantuoni; Piero Fregatti; Luca Boni; Matteo Lambertini; Lucia Del Mastro

doi:10.1016/j.esmoop.2024.103650

Abstract

The phase III GIM2 trial showed improved disease-free survival (DFS) and overall survival (OS) with adjuvant dose-dense (DD) as compared with standard-interval (SI) chemotherapy in women with node-positive early-stage breast cancer (BC). This exploratory analysis aimed to investigate the benefit of different schedules according to body mass index (BMI) in this trial.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Poggio et al. (2024) studied this question.

synapsesocial.com/papers/68e5dc5db6db6435875722e5 https://doi.org/10.1016/j.esmoop.2024.103650

View Full Paper

Ask AI

Bookmark

Share

Efficacy of adjuvant chemotherapy schedules for breast cancer according to body mass index: results from the phase III GIM2 trial

Abstract

Discussion

Cite This Study

Efficacy of adjuvant chemotherapy schedules for breast cancer according to body mass index: results from the phase III GIM2 trial

Abstract

Discussion

Cite This Study

Keep reading

Keep reading